AU2018236188B2 - Process for making hepatitis B core protein modulators - Google Patents

Process for making hepatitis B core protein modulators Download PDF

Info

Publication number
AU2018236188B2
AU2018236188B2 AU2018236188A AU2018236188A AU2018236188B2 AU 2018236188 B2 AU2018236188 B2 AU 2018236188B2 AU 2018236188 A AU2018236188 A AU 2018236188A AU 2018236188 A AU2018236188 A AU 2018236188A AU 2018236188 B2 AU2018236188 B2 AU 2018236188B2
Authority
AU
Australia
Prior art keywords
compound
formula
reaction
mmol
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018236188A
Other languages
English (en)
Other versions
AU2018236188A1 (en
Inventor
Lee D. Arnold
Leping Li
Sreenivasa Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assembly Biosciences Inc
Original Assignee
Assembly Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assembly Biosciences Inc filed Critical Assembly Biosciences Inc
Publication of AU2018236188A1 publication Critical patent/AU2018236188A1/en
Application granted granted Critical
Publication of AU2018236188B2 publication Critical patent/AU2018236188B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/02—Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2018236188A 2017-03-13 2018-03-13 Process for making hepatitis B core protein modulators Ceased AU2018236188B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762470560P 2017-03-13 2017-03-13
US62/470,560 2017-03-13
PCT/US2018/022100 WO2018169907A1 (en) 2017-03-13 2018-03-13 Process for making hepatitis b core protein modulators

Publications (2)

Publication Number Publication Date
AU2018236188A1 AU2018236188A1 (en) 2019-10-17
AU2018236188B2 true AU2018236188B2 (en) 2022-01-27

Family

ID=61768549

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018236188A Ceased AU2018236188B2 (en) 2017-03-13 2018-03-13 Process for making hepatitis B core protein modulators

Country Status (9)

Country Link
US (2) US11040965B2 (https=)
EP (1) EP3596070A1 (https=)
JP (1) JP7179751B2 (https=)
KR (1) KR102575605B1 (https=)
CN (1) CN110612300B (https=)
AU (1) AU2018236188B2 (https=)
CA (1) CA3056696A1 (https=)
SG (1) SG11201908475RA (https=)
WO (1) WO2018169907A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017326356A1 (en) 2016-09-15 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein modulators
SG11201908012SA (en) 2017-03-02 2019-09-27 Assembly Biosciences Inc Cyclic sulfamide compounds and methods of using same
SG11202112590WA (en) * 2019-05-24 2021-12-30 Assembly Biosciences Inc Pharmaceutical compositions for the treatment of hbv
CN111333513B (zh) * 2020-04-17 2021-08-27 江苏恒沛药物科技有限公司 一种2,4-二氟-3-硝基苯甲酸的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053157A1 (en) * 2016-09-15 2018-03-22 Assembly Biosciences, Inc. Hepatitis b core protein modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1480553A (en) 1976-06-03 1977-07-20 Pfizer Ltd Tricyclic sulphonamides
JPS58225074A (ja) 1982-06-25 1983-12-27 Chugai Pharmaceut Co Ltd ジベンゾオキサゼピン誘導体
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9707695D0 (en) * 1996-08-07 1997-06-04 Hoffmann La Roche Tricyclic dione derivatives
US20050192286A1 (en) * 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE102004004928A1 (de) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
CA2625423A1 (en) 2005-10-17 2007-04-26 Acadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
US20070105835A1 (en) 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
JP4042065B1 (ja) 2006-03-10 2008-02-06 健治 吉田 情報処理装置への入力処理システム
WO2008036139A2 (en) 2006-06-07 2008-03-27 The Regents Of The University Of California Inhibitors of mshc and homologs thereof, and methods of identifying same
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
CN102164605A (zh) 2008-07-23 2011-08-24 美国卫生和人力服务部 用作抗疟药的疟原虫表面阴离子通道抑制剂
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
EP3085368A1 (en) 2011-07-01 2016-10-26 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
US20150141384A1 (en) * 2012-07-03 2015-05-21 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
RU2519546C1 (ru) 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2015017412A1 (en) 2013-07-29 2015-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists
CN104803880B (zh) * 2014-01-23 2017-11-21 广州喜鹊医药有限公司 一种具有神经保护作用的化合物及其制备方法和应用
PT3116316T (pt) 2014-03-13 2019-09-30 Assembly Biosciences Inc Moduladores alostéricos da proteína do núcleo da hepatite b
WO2015189035A1 (en) 2014-06-10 2015-12-17 Basf Se Substituted [1,2,4]triazole and imidazole compounds as fungicides
TWI730985B (zh) 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053157A1 (en) * 2016-09-15 2018-03-22 Assembly Biosciences, Inc. Hepatitis b core protein modulators

Also Published As

Publication number Publication date
US11040965B2 (en) 2021-06-22
CN110612300A (zh) 2019-12-24
CA3056696A1 (en) 2019-09-20
WO2018169907A1 (en) 2018-09-20
AU2018236188A1 (en) 2019-10-17
US20210380577A1 (en) 2021-12-09
CN110612300B (zh) 2023-10-20
KR20190128675A (ko) 2019-11-18
SG11201908475RA (en) 2019-10-30
JP7179751B2 (ja) 2022-11-29
JP2020510059A (ja) 2020-04-02
EP3596070A1 (en) 2020-01-22
KR102575605B1 (ko) 2023-09-05
US20200002325A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
CN115322158B (zh) 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物
JP7653362B2 (ja) 二環式化合物
CN108699077B (zh) 作为rsv抑制剂的杂环化合物
CA3232128A1 (en) Pyridine derivative and use thereof
EP3805232B1 (en) Crystalline synthetic intermediate useful in processes for making a mdm2 inhibitor
JP2019151650A (ja) Ｂ型肝炎コアタンパク質アロステリックモジュレーター
JP5366349B2 (ja) ホスホジエステラーゼ阻害剤として有効な置換ピロロピリジノン誘導体
JP4667537B2 (ja) アシルチオウレア化合物又はその塩、及びその用途
AU2018236188B2 (en) Process for making hepatitis B core protein modulators
CA3079833A1 (en) Bridged bicyclic compounds as farnesoid x receptor modulators
CA2998741A1 (en) Hepatitis b core protein modulators
CA2772642A1 (en) Quinazolines as potassium ion channel inhibitors
CN105722840B (zh) 作为PI3K、mTOR抑制剂的稠合喹啉化合物
CA3191829A1 (en) Cd73 inhibitor and application thereof in medicine
AU2006216266C1 (en) Quinazoline derivative having tyrosine kinase inhibitory activity
CN114901639B (zh) Hbv抑制剂及其用途
CN114380837A (zh) 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
WO2005080392A1 (ja) ピラゾロキノロン誘導体およびその用途
WO2014181788A1 (ja) α－置換グリシンアミド誘導体
WO2025039979A1 (zh) 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
CN108948003B (zh) 作为mTOR抑制剂的吡嗪并[2,3-c]喹啉-2（1H）-酮类化合物的制备及用途
WO2016023522A2 (en) Substituted phosphoramidate compounds and uses thereof
CN120289428A (zh) 一种1-氧代异吲哚啉衍生物及其应用
TWI394757B (zh) 嘌呤衍生物及使用它之抗腫瘤劑
CN121342684A (zh) 一种n-芳基-2-萘甲酰胺类usp2抑制剂及其医药用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired